Nishihara M, Morikawa N, Yokoyama S, Nishikura K, Yasuhara M, Matsuo H
Pharmazie. 2018 Nov 1;73(11):671-675. doi: 10.1691/ph.2018.8664.
Bevacizumab has been reported to increase blood pressure. However, the factors, including patient characteristics and laboratory data contributing to this side effect remain unclear. Therefore, we investigated the relationships between increased blood pressure and bevacizumab administration, patient characteristics, and laboratory data. Between April 2007 and January 2018, factor analysis was retrospectively conducted by monitoring increases in blood pressure, the status of bevacizumab administration, patient characteristics, and laboratory data before the first administration in Japanese patients with colorectal cancer who satisfied the criteria for this study. Sixty-seven patients were included, 34 of whom (50.7%) had an increase in blood pressure after bevacizumab administration. On univariate analysis, liver metastasis, antihypertensive drug use, systolic blood pressure at rest before the first bevacizumab administration, body mass index, creatinine, and blood platelet count were significantly different between the two groups. Multivariate analysis was conducted using increased blood pressure as an objective variable and the factors extracted by the univariate analysis as explanatory variables. The results suggested that liver metastasis, antihypertensive drugs, systolic blood pressure at rest before the first bevacizumab administration, and creatinine were associated with the increase in blood pressure. Furthermore, a log-rank test performed based on Kaplan-Meier curves demonstrated that liver metastasis in patients not taking antihypertensive drugs and antihypertensive drug use in patients without liver metastasis were significantly associated with increased blood pressure. Additionally, liver metastasis in patients with antihypertensive drug use was significantly associated with increased blood pressure. Our findings suggest that liver metastasis and antihypertensive drug use, which was previously reported, are risk factors for increased blood pressure.
据报道，贝伐单抗会使血压升高。然而，导致这种副作用的因素，包括患者特征和实验室数据仍不清楚。因此，我们研究了血压升高与贝伐单抗给药、患者特征和实验室数据之间的关系。在2007年4月至2018年1月期间，对符合本研究标准的日本结直肠癌患者进行回顾性因素分析，监测首次给药前的血压升高情况、贝伐单抗给药状态、患者特征和实验室数据。纳入67例患者，其中34例（50.7%）在使用贝伐单抗后血压升高。单因素分析显示，两组之间肝转移、使用降压药、首次使用贝伐单抗前的静息收缩压、体重指数、肌酐和血小板计数存在显著差异。以血压升高作为目标变量，将单因素分析中提取的因素作为解释变量进行多因素分析。结果表明，肝转移、降压药、首次使用贝伐单抗前的静息收缩压和肌酐与血压升高有关。此外，基于Kaplan-Meier曲线进行的对数秩检验表明，未服用降压药患者的肝转移以及无肝转移患者使用降压药与血压升高显著相关。此外，使用降压药患者的肝转移与血压升高显著相关。我们的研究结果表明，先前报道的肝转移和使用降压药是血压升高的危险因素。
